Levodopa motor complications in Parkinson's disease

Parkinson, 1817

Olanow, 1998, An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines (American Academy of Neurology), Neurology, 50, 1, 10.1212/WNL.50.3_Suppl_3.S1

Jellinger, 1987, The pathology of parkinsonism, 124

Kish, 1988, Uneven pattern of dopamine loss in the striatum of patients with Parkinson's disease, New Engl. J. Med., 318, 876, 10.1056/NEJM198804073181402

Vingerhoets, 1994, Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions, Ann. Neurol., 36, 759, 10.1002/ana.410360512

Cotzias, 1967, Aromatic aminoacids and modification of parkinsonism, New Engl. J. Med., 276, 374, 10.1056/NEJM196702162760703

Hughes, 1992, Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases, J. Neurol. Neurosurg. Psychiatry, 55, 181, 10.1136/jnnp.55.3.181

Marsden, 1977, Success and problems of long-term levodopa therapy in Parkinson's disease, Lancet, 1, 345, 10.1016/S0140-6736(77)91146-1

Obeso, 1989, Motor complications associated with chronic levodopa therapy in Parkinson's disease, Neurology, 39, 11

Fénelon, 2000, Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors, Brain, 123, 733, 10.1093/brain/123.4.733

Hughes, 2000, A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease, Neurology, 54, 1596, 10.1212/WNL.54.8.1596

Rodriguez, 1998, Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection, Ann. Neurol., 44, 175, 10.1002/ana.410440726

Olanow, 1993, A radical hypothesis for neurodegeneration, Trends Neurosci., 16, 439, 10.1016/0166-2236(93)90070-3

Olanow, 1998, Cell death and neuroprotection in Parkinson's disease, 44

Benabid, 2000, Subthalamic deep brain stimulation, Prog. Neurolog. Surg., 15, 196, 10.1159/000062043

Olanow, C.W. and Brin, M.F. Surgery for Parkinson's disease: a physician's perspective. Adv. Neurol. (in press)

Olanow, 2000, Preventing levodopa-induced dyskinesias, Ann. Neurol., 47, 167

Grandas, 1999, Risk factors for levodopa-induced dyskinesias in Parkinson's disease, J. Neurol., 246, 1127, 10.1007/s004150050530

Colosimo, 1999, Motor fluctuations in Parkinson's disease: pathophysiology and treatment, Eur. J. Neurol., 6, 1, 10.1046/j.1468-1331.1999.610001.x

Marsden, 1982, Fluctuations of disability in Parkinson's disease: clinical aspects, 96

Fahn, 1982, Fluctuations of disability in Parkinson's disease: pathophysiology, 123

Quinn, 1987, Young onset Parkinson's disease, Mov. Disord., 2, 73, 10.1002/mds.870020201

Luquin, 1992, Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification, Mov. Disord., 7, 117, 10.1002/mds.870070204

Marconi, 1994, Levodopa-induced dyskinesias in Parkinson's disease: phenomenology and pathophysiology, Mov. Disord., 9, 2, 10.1002/mds.870090103

Muenter, 1977, Patterns of dystonia (‘I-D-I’ and ‘D-I-D’) in response to l-dopa therapy for Parkinson's disease, 52, 163

Fahn, 2000, The spectrum of levodopa-induced dyskinesias, Ann. Neurol., 47, 3

Barbeau, 1971, Long-term side effects of levodopa, Lancet, 1, 395, 10.1016/S0140-6736(71)92226-4

Bedard, 1986, Chronic treatment with l-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys, 379, 294

Langston, 1984, Chronic parkinsonism in humans due to a product of meperidine analog synthesis, Science, 225, 1480, 10.1126/science.6332378

Nutt, 1996, The response to levodopa in Parkinson's disease: imposing pharmacological law and order, Ann. Neurol., 39, 561, 10.1002/ana.410390504

Quinn, 1986, Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a 4 year period, Mov. Disord., 1, 65, 10.1002/mds.870010109

Hauser, 2000, Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease, Mov. Disord., 15, 485, 10.1002/1531-8257(200005)15:3<485::AID-MDS1010>3.0.CO;2-F

Nutt, 1992, Effect of long-term therapy on the pharmacodynamics of levodopa, 49, 1123

Fabbrini, 1987, Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease, Ann. Neurol., 21, 370, 10.1002/ana.410210409

Mouridian, 1987, Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies, Ann. Neurol., 22, 475, 10.1002/ana.410220406

Chase, 1986, Fluctuation in response to chronic levodopa therapy: pathogenetic and therapeutic considerations, Adv. Neurol., 45, 477

Papa, 1994, Motor fluctuations in levodopa-treated parkinsonian rats: relation to lesion extent and treatment duration, Brain Res., 662, 69, 10.1016/0006-8993(94)90796-X

Chase, 1989, Rationale for continuous dopaminomimetic therapy of Parkinson's disease, Neurology, 39, 7

Rodriguez, 1994, Motor response to apomorphine and levodopa in asymmetric Parkinson's disease, J. Neurol. Neurosurg. Psychiatry, 57, 562, 10.1136/jnnp.57.5.562

Grandas, 1992, Difference in the motor response to apomorphine between untreated and fluctuating patients with Parkinson's disease, Clin. Neuropharmacol., 15, 13, 10.1097/00002826-199202000-00002

Colosimo, 1996, Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon, J. Neurol. Neurosurg. Psychiatry, 60, 634, 10.1136/jnnp.60.6.634

Bravi, 1994, Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms, Ann. Neurol., 36, 27, 10.1002/ana.410360108

Nutt, 2000, Apomorphine can sustain the long-duration response to l-DOPA in fluctuating Parkinson's disease, Neurology, 54, 247, 10.1212/WNL.54.1.247

Limousin, 1998, Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease, New Engl. J. Med., 339, 1105, 10.1056/NEJM199810153391603

Linazasoro, 1997, Deep brain stimulation changes the magnitude of the motor response to levodopa in Parkinson's disease: pathophysiological implications, Soc. Neurosci. Abstr., 25, 1013

Bejjani, 2000, Levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible?, Ann. Neurol., 47, 655, 10.1002/1531-8249(200005)47:5<655::AID-ANA16>3.0.CO;2-#

Lang, 1997, Posteroventral medial pallidotomy in advanced Parkinson's disease, New Engl. J. Med., 337, 1036, 10.1056/NEJM199710093371503

Crossman, 1990, A hypothesis on the pathophysiological mechanisms that underlie levodopa or dopamine agonist-induced dyskinesia in Parkinson's disease, Mov. Disord., 5, 100, 10.1002/mds.870050203

Delong, 1990, Primate models of movement disorders of basal ganglia origin, Trends Neurosci., 13, 281, 10.1016/0166-2236(90)90110-V

Obeso, 2000, Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model, Ann. Neurol., 47, 22

Calon, 2000, Molecular basis of levodopa-induced dyskinesias, Ann. Neurol., 47, 70

Obeso, 1994, The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease, Eur. J. Neurosci., 6, 889, 10.1111/j.1460-9568.1994.tb00584.x

Brotchie, 2000, The neural mechanisms underlying levodopainduced dyskinesia in Parkinson's disease, Ann. Neurol., 47, 105

Gerfen, 2000, Dopamine-mediated gene regulation in models of Parkinson's disease, Ann. Neurol., 47, 42

Chase, 2000, Striatal mechanisms and pathogenesis of parkinsonian signs, Ann. Neurol., 47, 122

Calabresi, 1996, The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia, Trends Neurosci., 19, 19, 10.1016/0166-2236(96)81862-5

Jenner, 2000, Factors influencing the onset and persistence of dyskinesias in the parkinsonian primate, Ann. Neurol., 47, S90

Henry, 1999, Effect of repeated l-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat, Exp. Neurol., 155, 204, 10.1006/exnr.1998.6996

Obeso, 1988, Continuous dopaminergic stimulation for Parkinson's disease, J. Neural Transm., 27, 249

Olanow, 2000, Continuous dopaminergic-receptor stimulation in early Parkinson's disease, Trends Neurosci., 23, S117, 10.1016/S1471-1931(00)00030-6

Rascol, 2000, A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa, New Engl. J. Med., 342, 1484, 10.1056/NEJM200005183422004